|
|
Post by saxcmann on Mar 9, 2016 18:13:47 GMT -5
Sell to highest bidder. I'm happy with $5-10 bucks. Move on to something else maybe oil. Learned how corrupt and manipulative WS is!
|
|
|
|
Post by saxcmann on Mar 3, 2016 12:32:41 GMT -5
Just checked Fidelity, 45% Thanks! That's what they're paying TO retail shareholders, correct? Correct. |
|
|
|
Post by saxcmann on Mar 2, 2016 16:57:23 GMT -5
Afrezza needs "promotion". We haven't had that yet. We need a new marketing partner or sell the drug to someone that will!
|
|
|
|
Post by saxcmann on Mar 2, 2016 16:49:12 GMT -5
I believe contractually liable to complete meetings/training on afrezza until officially cancelled.
|
|
|
|
Post by saxcmann on Feb 19, 2016 11:32:08 GMT -5
I think it's more likely now that we get sold. Possibly someone wanted Al off the BOD and not attached to company before bidding? But yes, poor health could also be reason.
|
|
|
|
Post by saxcmann on Feb 18, 2016 9:13:24 GMT -5
I thought the shorts were supposed to be covering? Seriously, they smell blood in the water and won't start covering until we get down around two bits, maybe 50 cents if the Company surprises and shows any sign of life. Until then, fasten your seatbelts and hold on to your hope...  Shorts won't cover unless forced. At this point anything short of a afrezza buyout or complete buyout I think they won't cover. BP behind hedge play to force bankruptcy. Seatbelt is fastened... |
|
|
|
Post by saxcmann on Feb 11, 2016 9:16:35 GMT -5
You can make Afrezza free but if no one is aware of it then it won't matter.
Actually agree with your sentence above...
At this point I am not believing the value of Afrezza can be realized while mnkd holds the drug. Afrezza needs promotion.
|
|
|
|
Post by saxcmann on Feb 10, 2016 9:13:52 GMT -5
It's important that results are released in a peer reviewed publication. Hopefully, MannKind had some say in this process because I don't trust Sanofi to ensure that Afrezza study results are shown in the best light. Makes sense and is usually the way to roll out trial data. But, will it matter? Will the clamp data results make endos/pcps change their mind about Afrezza and embrace it as a viable weapon to fight diabetes? I'm not so sure it will. I hear scientific data is very important and how it is released. Positive clamp results would influence endos/pcps strongly. Currently data is insufficient. Doctor education and DTC marketing will also be very important for success,imo. |
|
|
|
Post by saxcmann on Jan 26, 2016 15:29:06 GMT -5
while i agree with you, i don't believe a company will come in and buy Mannkind right now anywhere near what we all think it's worth in the long run. Would you be willing to accept an offer under a billion? If MNKD is sold, it's because our hand was forced and not because Al Mann wanted it. Under a billion is laughable...never will happen. |
|
|
|
Post by saxcmann on Jan 10, 2016 21:24:21 GMT -5
...coming up in a few days with likely the most critical CC to come two trading days ahead. 60-80 million shares lose control and 30-40 million are in the money! Can any news change the pps short term?
|
|
|
|
Post by saxcmann on Jan 7, 2016 13:01:44 GMT -5
I did #3 and will join #7 if it happens.
|
|
|
|
Post by saxcmann on Jan 6, 2016 20:03:25 GMT -5
My email to Matt: Is the 65/35 split still in effect? Can MannKind reduce the price of Afrezza before July? Need an Afrezza sales rep in Chicago area? Matt's reply: Yes, yes and maybe... I can sell Afrezza in North Carolina. I guarantee I could sell more than Sanofi did! Tell Matt...I have a great reference. I heard Sanofi reps weren't even pushing afrezza unless a endo was already selling it. What a joke! |
|
|
|
Post by saxcmann on Jan 5, 2016 9:26:02 GMT -5
I am shocked! Everything I was saying was honest and direct from Sanofi reps. I promise they had know idea as well. I hope and pray this is not game over and a new partner will come soon! Again, I'm shocked like everyone else!
Always mannkind long!
|
|
|
|
Post by saxcmann on Dec 17, 2015 16:58:45 GMT -5
Thanks sports. Did you see the 20U comment? Also Sanofi speaker training for doctor training will start in February. Gotta a feeling we'll hear news before then...
|
|
|
|
Post by saxcmann on Dec 15, 2015 12:18:59 GMT -5
This may not be a controlled launch by design. But the low awareness of Afrezza among doctors and physicians suggests that at least Sanofi is not spending a big efforts in getting the messages out to the doctors and physicians. In that sense, I think one can still view the launch as a controlled launch. It's kindly of like they arrive under an apple tree, and instead of climbing on the tree to pick the apples one by one, they just lazily throw a couple of stones at the trees and see what happens. I think Sanofi did hold back its efforts in the marketing of Afrezza while they collect, observe and evaluate the feedbacks from users in real life. Therefore, I believe, once they use their full efforts, the scripts will be significantly higher than the current level. I highly doubt it is low awareness in the Endocronology field. They all have continuing education, they all read journals, they are aware of Afrezza. Patients may not be aware, but you are just spreading lies to believe that the medical community is not aware of Afrezza at this point. I strongly disagree with your comments above traderdennis. In general Endos are simply not that familiar with how afrezza works yet. On going training for docs is very important. Also, your comments above about lung issues is a joke. |
|
